Medherant is a University of Warwick spin-out clinical-stage biotechnology company developing a testosterone replacement patch for women with menopausal symptoms. The patch is based on a proprietary adhesive developed by its scientists, designed to deliver the correct amount of hormone and to be changed twice a week. Led by CEO John Burt, the company plans to begin clinical trials later this year and to seek regulatory approval in the UK and internationally. Medherant raised £3M in funding from Mercia Asset Management and intends to use the proceeds to accelerate growth and research efforts. The company is focused on advancing through clinical stages and progressing its product toward regulatory review. Medherant Limited is a University of Warwick spinout developing an innovative transdermal drug-delivery patch platform, TEPI Patch®. Led by CEO Nigel Davis, the proprietary TEPI Patch® is designed to deliver higher doses of drugs through the skin to act locally or systemically. The company plans to move its ibuprofen TEPI Patch® into clinical development and commercialize it, and to initiate development of a lidocaine TEPI Patch®. It has an exclusive licence agreement with Bostik SA to use the firm’s novel pressure sensitive adhesive material in TEPI Patch® development. Medherant raised £3.8m in this funding round, with existing investor Mercia Technologies PLC investing £2.5m and now owning 32.4%. Mercia first invested in June 2015 through its managed funds. Medherant is a University of Warwick spinout that has developed a transdermal drug delivery system in the form of a patch. The company's core product is a transdermal patch for drug delivery. Mercia Technologies announced it had completed a new direct investment of £650,000 into Medherant. The investment was disclosed in a Stock Exchange announcement referenced by Mercia. Mercia described the placement as a direct investment. The article does not provide additional operational metrics or future plans.

Total raised

$11M

Funding rounds

3

Latest round

Equity

Latest activity

Apr 2023